Weekly Report: what happened at MGNX last week (0610-0614)?
Weekly Report · 5d ago
MacroGenics Insider Ups Holding By 83% During Year
Insiders were net buyers of MacroGenics, Inc.'s stock in the last year. The biggest single purchase by an insider was when Edward Hurwitz bought US$74k worth of shares at a price of US$4.91 per share. In the last 12 months,  insiders have bought more shares in the company than they sold.  MacroGenics insiders own 2.7% of the company. You can see the insider transactions of Macrogenics over the lastyear.
Simply Wall St · 06/12 10:13
MacroGenics to Participate in Upcoming Investor Conference
Barchart · 06/11 06:45
Weekly Report: what happened at MGNX last week (0603-0607)?
Weekly Report · 06/10 09:04
Reuters · 06/04 20:54
Buy Rating Affirmed for MacroGenics Amidst Promising Oncology Pipeline and Strategic Positioning
Analyst Mayank Mamtani from B.Riley Financial reiterated a Buy rating on MacroGenics (MGNX – Research Report) and kept the price target at $18.00. The company is developing a next-generation B7-H3 targeted antibody-drug conjugates.
TipRanks · 06/03 23:45
Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session
SAIC shares dipped 11% to $119.91 following first-quarter results. GameStop Corp. Shares climbed 34.5% after Roaring Kitty on a Reddit post, shared his position on the stock. Microbot Medical Inc. Shares jumped 92.5%; Bio-Path Holdings, Inc. Jumped 75%.
Benzinga · 06/03 17:56
Monday Sector Leaders: Biotechnology, Drugs
NASDAQ · 06/03 15:59
MacroGenics (MGNX) Gets a Hold from TD Cowen
TipRanks · 06/03 11:36
Weekly Report: what happened at MGNX last week (0527-0531)?
Weekly Report · 06/03 09:05
Weekly Report: what happened at MGNX last week (0520-0524)?
Weekly Report · 05/27 09:05
Demystifying Macrogenics: Insights From 14 Analyst Reviews
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Macrogenics has 14 analysts' ratings that vary from bullish to bearish over the last quarter. The company has a 12-month price target of $.
Benzinga · 05/24 18:00
Macrogenics Price Target Cut to $9.00/Share From $24.00 by BTIG
Dow Jones · 05/24 17:11
Macrogenics Is Maintained at Buy by BTIG
Dow Jones · 05/24 17:11
BTIG Maintains Buy on Macrogenics, Lowers Price Target to $9
Benzinga · 05/24 17:02
Analysts Offer Insights on Healthcare Companies: MacroGenics (MGNX) and Iovance Biotherapeutics (IOVA)
TipRanks · 05/24 16:40
Analysts Are Bullish on These Healthcare Stocks: MacroGenics (MGNX), Iovance Biotherapeutics (IOVA)
TipRanks · 05/24 16:30
U.S. RESEARCH ROUNDUP-Deckers Brands, Nvidia, Workday
Wall Street securities analysts revise their ratings and price targets on several companies. Deckers Brands, Nvidia and Workday are among the companies. Barclays raises target price to $1089 from $1026 for Deckers brands. Deutsche Bank raises price target for Nvidia to $1000.
Reuters · 05/24 07:14
Reuters · 05/24 04:40
Analysts Conflicted on These Healthcare Names: MacroGenics (MGNX) and Medtronic (MDT)
TipRanks · 05/23 22:50
Webull provides a variety of real-time MGNX stock news. You can receive the latest news about Macrogenics Inc through multiple platforms. This information may help you make smarter investment decisions.
About MGNX
MacroGenics, Inc. is a biopharmaceutical company focused on developing and commercializing monoclonal antibody-based therapeutics for the treatment of cancer. It generates its pipeline of product candidates primarily from its suite of antibody-based technology platforms, which have applicability across broad therapeutic domains. It is developing product candidates that target various tumor-associated antigens and immune checkpoint molecules. Its lead pipeline program is vobramitamab duocarmazine (vobra duo), an antibody-drug conjugate (ADC) that targets B7-H3, a molecule in the B7 family of immune regulator proteins that is expressed by several different tumor types. Its clinical pipeline includes two product candidates based on its, bispecific DART technology that co-engages both PD-1 and other checkpoint molecules. These candidates include lorigerlimab and tebotelimab. In addition, it is developing MGD024, a bispecific DART molecule. It is also developing various other programs.